# ROCHE HLDG P

Summary updated: 2026-03-19T21:00:26.252687Z
Canonical: https://finbar.com/research/companies/roche-hldg-p

## Overview

Roche Holding AG is a Swiss healthcare company founded in Basel in 1896, with two core businesses: Pharmaceuticals and Diagnostics. The group develops and markets prescription medicines as well as diagnostic solutions, including in vitro diagnostics and digital tools used across the patient pathway from screening and diagnosis to treatment selection and monitoring [1](https://app.finbar.com/go?id=P-64eff0b0ee454199b0a59cdd7d97a2ca)[2](https://app.finbar.com/go?id=P-c88b18e5ca484eb686e4eb1ed85758c9)[3](https://www.roche.com/about/business)[4](https://www.roche.com/about/business/diagnostics). Roche describes its mission as “Doing now what patients need next” and says its purpose is to improve outcomes by helping prevent, stop or cure diseases [5](https://app.finbar.com/go?id=P-5659f48e0a6c4108ae1d0b4da9531543)[6](https://www.roche.com/about/strategy)[7](https://www.roche.com/about/our_purpose.htm).

The company has a broad international footprint, with reported sales across Europe, North America, Latin America, Japan, the rest of Asia, and Africa/Australia/Oceania, and it states that it employs more than 100,000 people worldwide [8](https://app.finbar.com/go?id=P-92b3d84dd9f04e0da3f1fbeaeacb313b)[9](https://careers.roche.com/global/en/why-join-us). In 2024, Roche generated CHF 60.5 billion in sales, with Pharmaceuticals and Diagnostics remaining the defining segments of the group’s operations [10](https://app.finbar.com/go?id=P-460f9eef914a4c41b9f5eabc734512d1)[11](https://app.finbar.com/go?id=T-2359993e791b46d39290f3ba779cbf2b).
[1](https://app.finbar.com/go?id=P-64eff0b0ee454199b0a59cdd7d97a2ca)[2](https://app.finbar.com/go?id=P-c88b18e5ca484eb686e4eb1ed85758c9)[5](https://app.finbar.com/go?id=P-5659f48e0a6c4108ae1d0b4da9531543)[8](https://app.finbar.com/go?id=P-92b3d84dd9f04e0da3f1fbeaeacb313b)[10](https://app.finbar.com/go?id=P-460f9eef914a4c41b9f5eabc734512d1)[11](https://app.finbar.com/go?id=T-2359993e791b46d39290f3ba779cbf2b)[3](https://www.roche.com/about/business)[4](https://www.roche.com/about/business/diagnostics)[6](https://www.roche.com/about/strategy)[7](https://www.roche.com/about/our_purpose.htm)[9](https://careers.roche.com/global/en/why-join-us)

## Products & services

Roche’s products are split between prescription medicines and diagnostics. In 2024, Pharmaceuticals generated CHF 46.2 billion of sales versus CHF 14.3 billion for Diagnostics, so medicines represented roughly three-quarters of group sales and diagnostics about one-quarter; within Pharmaceuticals, oncology/haematology was the largest category at CHF 23.7 billion, followed by neurology at CHF 9.3 billion, immunology at CHF 6.3 billion and ophthalmology at CHF 4.0 billion.[12](https://app.finbar.com/go?id=P-d938979cb56b4bdf970d841020263657)[13](https://app.finbar.com/go?id=P-9596a432a585438f9816b34c3098c78f)[14](https://app.finbar.com/go?id=T-d707a7ec58dd40c7b74f2d770b9b9adb)

Key medicines include Ocrevus for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis, which was Roche’s largest single product at CHF 6.7 billion of 2024 sales; Hemlibra for haemophilia A at CHF 4.5 billion; Vabysmo for neovascular or “wet” age-related macular degeneration, diabetic macular oedema and macular oedema following retinal vein occlusion at CHF 3.9 billion; and Tecentriq for cancers including extensive-stage small cell lung cancer, non-squamous non-small cell lung cancer, hepatocellular carcinoma, bladder cancer and PD-L1-positive triple-negative breast cancer at CHF 3.6 billion.[14](https://app.finbar.com/go?id=T-d707a7ec58dd40c7b74f2d770b9b9adb)[15](https://app.finbar.com/go?id=P-3776404b52e342d9b5500948f6320fde)[16](https://app.finbar.com/go?id=P-179aef88c0b64553a365fa46e01e6c34)[17](https://app.finbar.com/go?id=P-bdacc548691b4d94826f3af47e1baf22)[18](https://app.finbar.com/go?id=P-fcc52c68aa3b40e1a8a065c0e6281e72) The HER2 franchise combines Perjeta, Kadcyla, Herceptin and Phesgo for HER2-positive breast cancer, with Herceptin also used in HER2-positive metastatic gastric cancer.[19](https://app.finbar.com/go?id=P-25d01a9fcf294baea8f89196ff457eec) Other notable products include Xolair for chronic spontaneous urticaria, allergic asthma and food allergies, Actemra/RoActemra for rheumatoid arthritis and other inflammatory indications, and Evrysdi for spinal muscular atrophy.[20](https://app.finbar.com/go?id=P-febe3f0034b74e988dfa2f0bdd9a7dff)[21](https://app.finbar.com/go?id=P-fae2ac9185764dfc8a987f56d9b0852c)[22](https://app.finbar.com/go?id=P-492c686c1c1f4ab1be4f1b6ef26a423e)

Roche’s diagnostics offerings include central-lab immunoassays, clinical chemistry and custom biotech solutions; molecular diagnostics for pathogen detection and monitoring, donor screening, sexual health and genomics; decentralized testing and integrated personalised diabetes management; and pathology-lab products for tissue biopsies and companion diagnostics.[23](https://app.finbar.com/go?id=P-6b4ac76bd0b4447b9988d28e1199967d)[24](https://app.finbar.com/go?id=P-89b6113d082f4d01b4e94ed251653032)[25](https://app.finbar.com/go?id=P-6584301c6fc8479c922e244799d554b4)[26](https://app.finbar.com/go?id=P-0c6b2fa51d71469e98a2ffba7dacfdf4) Specific platforms and services mentioned include Foundation Medicine genomic profiling tests, SARS-CoV-2 assays on the cobas 6800/8800 systems, the cobas liat molecular point-of-care line, and companion diagnostics and advanced staining solutions used to help select targeted therapies for individual patients.[24](https://app.finbar.com/go?id=P-89b6113d082f4d01b4e94ed251653032)[25](https://app.finbar.com/go?id=P-6584301c6fc8479c922e244799d554b4)[26](https://app.finbar.com/go?id=P-0c6b2fa51d71469e98a2ffba7dacfdf4)
[12](https://app.finbar.com/go?id=P-d938979cb56b4bdf970d841020263657)[13](https://app.finbar.com/go?id=P-9596a432a585438f9816b34c3098c78f)[14](https://app.finbar.com/go?id=T-d707a7ec58dd40c7b74f2d770b9b9adb)[15](https://app.finbar.com/go?id=P-3776404b52e342d9b5500948f6320fde)[16](https://app.finbar.com/go?id=P-179aef88c0b64553a365fa46e01e6c34)[17](https://app.finbar.com/go?id=P-bdacc548691b4d94826f3af47e1baf22)[18](https://app.finbar.com/go?id=P-fcc52c68aa3b40e1a8a065c0e6281e72)[19](https://app.finbar.com/go?id=P-25d01a9fcf294baea8f89196ff457eec)[20](https://app.finbar.com/go?id=P-febe3f0034b74e988dfa2f0bdd9a7dff)[21](https://app.finbar.com/go?id=P-fae2ac9185764dfc8a987f56d9b0852c)[22](https://app.finbar.com/go?id=P-492c686c1c1f4ab1be4f1b6ef26a423e)[23](https://app.finbar.com/go?id=P-6b4ac76bd0b4447b9988d28e1199967d)[24](https://app.finbar.com/go?id=P-89b6113d082f4d01b4e94ed251653032)[25](https://app.finbar.com/go?id=P-6584301c6fc8479c922e244799d554b4)[26](https://app.finbar.com/go?id=P-0c6b2fa51d71469e98a2ffba7dacfdf4)

## Geographic presence

Roche Holding Ltd is based in Basel, Switzerland, and the group reports geographic sales by customer destination rather than by production location [27](https://app.finbar.com/go?id=P-7f7f103577c4407f9a905b23a049bb8c)[28](https://app.finbar.com/go?id=T-d98e7bf438564ecd9f2e98de3d420579)[29](https://app.finbar.com/go?id=P-a3803e3c403b462ea50a1c1d798ad8b5). In 2024, external customer sales were concentrated in North America at CHF 29.8 billion, or about 49% of total sales, followed by Europe at CHF 14.0 billion, or about 23%, Asia at CHF 12.2 billion, or about 20%, Latin America at CHF 3.2 billion, or about 5%, and Africa, Australia and Oceania at CHF 1.3 billion, or about 2%; Switzerland accounted for CHF 747 million within the European total [30](https://app.finbar.com/go?id=T-df8d8f212e9f4b908c8cbaa4c3e4b199).

The Pharmaceuticals division is even more weighted to the US, which represented CHF 24.8 billion, or 53.7%, of divisional sales in 2024; Europe represented CHF 8.8 billion, or 19.1%, Japan CHF 2.9 billion, or 6.2%, and International markets CHF 9.7 billion, or 21.0%, with China contributing CHF 2.9 billion, or 6.3%, within International [31](https://app.finbar.com/go?id=T-4eee1d4ba9ef4df188d3c526fee3b94d). Diagnostics had a more balanced regional mix: Europe, Middle East and Africa generated CHF 4.8 billion, or 33.7%, of divisional sales, North America CHF 4.3 billion, or 30.3%, Asia-Pacific CHF 4.1 billion, or 28.6%, and Latin America CHF 1.1 billion, or 7.4%; within that, the US contributed CHF 3.9 billion and China CHF 2.4 billion [32](https://app.finbar.com/go?id=T-370b7a79420f416d85515485ebe2fca0).

Roche’s legal-entity footprint spans major markets across Europe, North America, Asia-Pacific, Latin America, the Middle East and Africa, with principal office locations listed in cities including Basel, Zurich, Vienna, Monza, London/Welwyn Garden City, Munich/Mannheim/Grenzach-Wyhlen, Tokyo, Shanghai, Singapore, Mississauga, Buenos Aires, Bogotá, Cairo, Sydney and North Ryde [33](https://app.finbar.com/go?id=P-defc4755e00341d38810b46fadf7a3aa)[28](https://app.finbar.com/go?id=T-d98e7bf438564ecd9f2e98de3d420579)[34](https://app.finbar.com/go?id=T-0760aa3790ed4796a20f3e46ec777b48)[35](https://app.finbar.com/go?id=T-15cd8c28948e43e19a16ab2e30a3df39)[36](https://app.finbar.com/go?id=T-bffc8a03f9174a0eba1275438639561e)[37](https://app.finbar.com/go?id=T-23e019b89163425aa17001000dca2683). On location-specific headcount, Roche says it has 13,600 employees in Switzerland across Basel, Kaiseraugst, Rotkreuz, Schlieren and Buonas, and 8,000+ employees across 10 locations in the United States [38](https://careers.roche.com/global/en/switzerland)[39](https://careers.roche.com/global/en/usa/).
[27](https://app.finbar.com/go?id=P-7f7f103577c4407f9a905b23a049bb8c)[28](https://app.finbar.com/go?id=T-d98e7bf438564ecd9f2e98de3d420579)[29](https://app.finbar.com/go?id=P-a3803e3c403b462ea50a1c1d798ad8b5)[30](https://app.finbar.com/go?id=T-df8d8f212e9f4b908c8cbaa4c3e4b199)[31](https://app.finbar.com/go?id=T-4eee1d4ba9ef4df188d3c526fee3b94d)[32](https://app.finbar.com/go?id=T-370b7a79420f416d85515485ebe2fca0)[33](https://app.finbar.com/go?id=P-defc4755e00341d38810b46fadf7a3aa)[34](https://app.finbar.com/go?id=T-0760aa3790ed4796a20f3e46ec777b48)[35](https://app.finbar.com/go?id=T-15cd8c28948e43e19a16ab2e30a3df39)[36](https://app.finbar.com/go?id=T-bffc8a03f9174a0eba1275438639561e)[37](https://app.finbar.com/go?id=T-23e019b89163425aa17001000dca2683)[38](https://careers.roche.com/global/en/switzerland)[39](https://careers.roche.com/global/en/usa/)

## Business segments

Roche officially reports two divisions: Pharmaceuticals and Diagnostics. Pharmaceuticals generates revenue from prescription medicines, while Diagnostics sells diagnostic instruments, reagents and consumables; residual activities are reported as Corporate. Roche also presents subdivisional information within Pharmaceuticals for Roche Pharmaceuticals and Chugai.[2](https://app.finbar.com/go?id=P-c88b18e5ca484eb686e4eb1ed85758c9) In 2024, Pharmaceuticals contributed CHF 46.2 billion of sales, or about 76% of group sales, and Diagnostics contributed CHF 14.3 billion, or about 24%.[12](https://app.finbar.com/go?id=P-d938979cb56b4bdf970d841020263657)[40](https://app.finbar.com/go?id=P-676c15d4c95f4138823417b5a8cf02b7)[41](https://app.finbar.com/go?id=T-4c68df3b264a47a79cdf93821f5f541c) Within Pharmaceuticals, Roche Pharmaceuticals accounted for CHF 43.3 billion of external sales and Chugai CHF 2.9 billion, roughly 94% and 6% of Pharmaceuticals sales, respectively.[2](https://app.finbar.com/go?id=P-c88b18e5ca484eb686e4eb1ed85758c9)[42](https://app.finbar.com/go?id=T-16687ec231564c0cafe401a7f166fb29)

Roche further analyzes Pharmaceuticals by therapeutic area rather than as separate operating segments. In 2024, Oncology/Haematology represented 51.4% of Pharmaceuticals sales, Neurology 20.1%, Immunology 13.7%, Ophthalmology 8.7%, and Other therapeutic areas 6.1%.[43](https://app.finbar.com/go?id=P-5b3691d6822548049d5838c01dca8958) The reported focus areas are: oncology/haematology, including products such as Phesgo, Hemlibra and Polivy; neurology, led by Ocrevus, Evrysdi and Elevidys; immunology, including Actemra/RoActemra and Xolair; and ophthalmology, where Vabysmo is the main growth driver.[44](https://app.finbar.com/go?id=P-0167cdbcd9c74b86b5d6905ad3df855a)[45](https://app.finbar.com/go?id=P-eb5c699c46be48c5b0474afd7d72647d)[46](https://app.finbar.com/go?id=P-a9da96f44d2c473880490088b60e74a1)[47](https://app.finbar.com/go?id=P-777204a36de64425b4e69a5c4bfdd113)

Diagnostics is broken down by customer area. In 2024, Core Lab contributed 55.9% of Diagnostics sales, Molecular Lab 18.1%, Near Patient Care 15.1%, and Pathology Lab 10.9%.[48](https://app.finbar.com/go?id=T-9bd7818491cc46ac985fe49e59f22e86) Core Lab focuses on central labs with immunoassays, clinical chemistry and custom biotech; Molecular Lab focuses on pathogen detection and monitoring, donor screening, sexual health and genomics, and includes Foundation Medicine; Near Patient Care covers decentralized settings such as emergency rooms, GP practices and direct-to-patient testing, including integrated personalized diabetes management; and Pathology Lab focuses on tissue biopsies and companion diagnostics.[23](https://app.finbar.com/go?id=P-6b4ac76bd0b4447b9988d28e1199967d)[24](https://app.finbar.com/go?id=P-89b6113d082f4d01b4e94ed251653032)[25](https://app.finbar.com/go?id=P-6584301c6fc8479c922e244799d554b4)[26](https://app.finbar.com/go?id=P-0c6b2fa51d71469e98a2ffba7dacfdf4) Roche notes that Foundation Medicine was transferred from Pharmaceuticals to Diagnostics effective 1 January 2024, with comparatives restated.[49](https://app.finbar.com/go?id=P-1ae0c31e14684c4db9d77c4c4f87064e)
[2](https://app.finbar.com/go?id=P-c88b18e5ca484eb686e4eb1ed85758c9)[12](https://app.finbar.com/go?id=P-d938979cb56b4bdf970d841020263657)[40](https://app.finbar.com/go?id=P-676c15d4c95f4138823417b5a8cf02b7)[41](https://app.finbar.com/go?id=T-4c68df3b264a47a79cdf93821f5f541c)[42](https://app.finbar.com/go?id=T-16687ec231564c0cafe401a7f166fb29)[43](https://app.finbar.com/go?id=P-5b3691d6822548049d5838c01dca8958)[44](https://app.finbar.com/go?id=P-0167cdbcd9c74b86b5d6905ad3df855a)[45](https://app.finbar.com/go?id=P-eb5c699c46be48c5b0474afd7d72647d)[46](https://app.finbar.com/go?id=P-a9da96f44d2c473880490088b60e74a1)[47](https://app.finbar.com/go?id=P-777204a36de64425b4e69a5c4bfdd113)[48](https://app.finbar.com/go?id=T-9bd7818491cc46ac985fe49e59f22e86)[23](https://app.finbar.com/go?id=P-6b4ac76bd0b4447b9988d28e1199967d)[24](https://app.finbar.com/go?id=P-89b6113d082f4d01b4e94ed251653032)[25](https://app.finbar.com/go?id=P-6584301c6fc8479c922e244799d554b4)[26](https://app.finbar.com/go?id=P-0c6b2fa51d71469e98a2ffba7dacfdf4)[49](https://app.finbar.com/go?id=P-1ae0c31e14684c4db9d77c4c4f87064e)

## Company history

Roche was founded in Basel, Switzerland, on 1 October 1896 by Fritz Hoffmann. In its early decades, it expanded internationally and established itself through scientifically developed medicines, including Digalen in 1904, while building a presence in multiple countries before the First World War. In 1934, Roche became the first company to mass-produce vitamins, an important step in its industrial and scientific development.[50](https://www.roche.com/about/history.htm)

After the Second World War, Roche added several major product and technology milestones. These included Rimifon for tuberculosis in 1952, a significant move into diagnostics in 1968, the Cobas Bio automated laboratory system in 1979, and Roferon-A, a genetically engineered cancer therapy, in 1986. In the 1990s, Roche acquired PCR technology in 1991, introduced a protease inhibitor for AIDS in 1995, and launched MabThera/Rituxan in 1997, which Roche describes as the first targeted antibody cancer drug.[50](https://www.roche.com/about/history.htm)[51](https://assets.roche.com/imported/07_Annual_Report_2022.pdf)

Roche also reshaped the group through major transactions. It acquired Boehringer Mannheim in 1998, a deal that significantly strengthened its diagnostics activities, then completed an alliance with Chugai in Japan in 2002. Roche later bought the remaining non-controlling interests in Genentech effective 26 March 2009, marking the full integration of one of its most important biotechnology businesses into the group.[50](https://www.roche.com/about/history.htm)[52](https://app.finbar.com/go?id=P-d6bdeb88c0a947a69a35b1676d0968f0)[53](https://app.finbar.com/go?id=P-aa6e749b0e0645e29b0fa61c087b1b7c)
[52](https://app.finbar.com/go?id=P-d6bdeb88c0a947a69a35b1676d0968f0)[53](https://app.finbar.com/go?id=P-aa6e749b0e0645e29b0fa61c087b1b7c)[50](https://www.roche.com/about/history.htm)[51](https://assets.roche.com/imported/07_Annual_Report_2022.pdf)

## Sources

1. [ROCHE HLDG P — Press release (2024 Y), p12](https://app.finbar.com/go?id=P-64eff0b0ee454199b0a59cdd7d97a2ca)
2. [ROCHE HLDG P — Full financial report (2024 Y), p57](https://app.finbar.com/go?id=P-c88b18e5ca484eb686e4eb1ed85758c9)
3. [www.roche.com](https://www.roche.com/about/business)
4. [www.roche.com](https://www.roche.com/about/business/diagnostics)
5. [ROCHE HLDG P — Presentation (2024 Y), p76](https://app.finbar.com/go?id=P-5659f48e0a6c4108ae1d0b4da9531543)
6. [www.roche.com](https://www.roche.com/about/strategy)
7. [www.roche.com](https://www.roche.com/about/our_purpose.htm)
8. [ROCHE HLDG P — Full financial report (2024 Y), p60](https://app.finbar.com/go?id=P-92b3d84dd9f04e0da3f1fbeaeacb313b)
9. [careers.roche.com](https://careers.roche.com/global/en/why-join-us)
10. [ROCHE HLDG P — Full financial report (2024 Y), p3](https://app.finbar.com/go?id=P-460f9eef914a4c41b9f5eabc734512d1)
11. [ROCHE HLDG P — Full financial report (2024 Y), p2](https://app.finbar.com/go?id=T-2359993e791b46d39290f3ba779cbf2b)
12. [ROCHE HLDG P — Full financial report (2024 Y), p15](https://app.finbar.com/go?id=P-d938979cb56b4bdf970d841020263657)
13. [ROCHE HLDG P — Full financial report (2024 Y), p28](https://app.finbar.com/go?id=P-9596a432a585438f9816b34c3098c78f)
14. [ROCHE HLDG P — Full financial report (2024 Y), p16](https://app.finbar.com/go?id=T-d707a7ec58dd40c7b74f2d770b9b9adb)
15. [ROCHE HLDG P — Full financial report (2024 Y), p17](https://app.finbar.com/go?id=P-3776404b52e342d9b5500948f6320fde)
16. [ROCHE HLDG P — Full financial report (2024 Y), p17](https://app.finbar.com/go?id=P-179aef88c0b64553a365fa46e01e6c34)
17. [ROCHE HLDG P — Full financial report (2024 Y), p19](https://app.finbar.com/go?id=P-bdacc548691b4d94826f3af47e1baf22)
18. [ROCHE HLDG P — Full financial report (2024 Y), p19](https://app.finbar.com/go?id=P-fcc52c68aa3b40e1a8a065c0e6281e72)
19. [ROCHE HLDG P — Full financial report (2024 Y), p18](https://app.finbar.com/go?id=P-25d01a9fcf294baea8f89196ff457eec)
20. [ROCHE HLDG P — Full financial report (2024 Y), p20](https://app.finbar.com/go?id=P-febe3f0034b74e988dfa2f0bdd9a7dff)
21. [ROCHE HLDG P — Full financial report (2024 Y), p19](https://app.finbar.com/go?id=P-fae2ac9185764dfc8a987f56d9b0852c)
22. [ROCHE HLDG P — Full financial report (2024 Y), p20](https://app.finbar.com/go?id=P-492c686c1c1f4ab1be4f1b6ef26a423e)
23. [ROCHE HLDG P — Full financial report (2024 Y), p28](https://app.finbar.com/go?id=P-6b4ac76bd0b4447b9988d28e1199967d)
24. [ROCHE HLDG P — Full financial report (2024 Y), p28](https://app.finbar.com/go?id=P-89b6113d082f4d01b4e94ed251653032)
25. [ROCHE HLDG P — Full financial report (2024 Y), p28](https://app.finbar.com/go?id=P-6584301c6fc8479c922e244799d554b4)
26. [ROCHE HLDG P — Full financial report (2024 Y), p28](https://app.finbar.com/go?id=P-0c6b2fa51d71469e98a2ffba7dacfdf4)
27. [ROCHE HLDG P — Full financial report (2024 Y), p4](https://app.finbar.com/go?id=P-7f7f103577c4407f9a905b23a049bb8c)
28. [ROCHE HLDG P — Full financial report (2024 Y), p141](https://app.finbar.com/go?id=T-d98e7bf438564ecd9f2e98de3d420579)
29. [ROCHE HLDG P — Full financial report (2024 Y), p60](https://app.finbar.com/go?id=P-a3803e3c403b462ea50a1c1d798ad8b5)
30. [ROCHE HLDG P — Full financial report (2024 Y), p60](https://app.finbar.com/go?id=T-df8d8f212e9f4b908c8cbaa4c3e4b199)
31. [ROCHE HLDG P — Full financial report (2024 Y), p22](https://app.finbar.com/go?id=T-4eee1d4ba9ef4df188d3c526fee3b94d)
32. [ROCHE HLDG P — Full financial report (2024 Y), p28](https://app.finbar.com/go?id=T-370b7a79420f416d85515485ebe2fca0)
33. [ROCHE HLDG P — Full financial report (2024 Y), p141](https://app.finbar.com/go?id=P-defc4755e00341d38810b46fadf7a3aa)
34. [ROCHE HLDG P — Full financial report (2024 Y), p141](https://app.finbar.com/go?id=T-0760aa3790ed4796a20f3e46ec777b48)
35. [ROCHE HLDG P — Full financial report (2024 Y), p142](https://app.finbar.com/go?id=T-15cd8c28948e43e19a16ab2e30a3df39)
36. [ROCHE HLDG P — Full financial report (2024 Y), p143](https://app.finbar.com/go?id=T-bffc8a03f9174a0eba1275438639561e)
37. [ROCHE HLDG P — Full financial report (2024 Y), p144](https://app.finbar.com/go?id=T-23e019b89163425aa17001000dca2683)
38. [careers.roche.com](https://careers.roche.com/global/en/switzerland)
39. [careers.roche.com](https://careers.roche.com/global/en/usa/)
40. [ROCHE HLDG P — Full financial report (2024 Y), p6](https://app.finbar.com/go?id=P-676c15d4c95f4138823417b5a8cf02b7)
41. [ROCHE HLDG P — Full financial report (2024 Y), p6](https://app.finbar.com/go?id=T-4c68df3b264a47a79cdf93821f5f541c)
42. [ROCHE HLDG P — Full financial report (2024 Y), p58](https://app.finbar.com/go?id=T-16687ec231564c0cafe401a7f166fb29)
43. [ROCHE HLDG P — Full financial report (2024 Y), p61](https://app.finbar.com/go?id=P-5b3691d6822548049d5838c01dca8958)
44. [ROCHE HLDG P — Full financial report (2024 Y), p15](https://app.finbar.com/go?id=P-0167cdbcd9c74b86b5d6905ad3df855a)
45. [ROCHE HLDG P — Full financial report (2024 Y), p15](https://app.finbar.com/go?id=P-eb5c699c46be48c5b0474afd7d72647d)
46. [ROCHE HLDG P — Full financial report (2024 Y), p15](https://app.finbar.com/go?id=P-a9da96f44d2c473880490088b60e74a1)
47. [ROCHE HLDG P — Full financial report (2024 Y), p15](https://app.finbar.com/go?id=P-777204a36de64425b4e69a5c4bfdd113)
48. [ROCHE HLDG P — Full financial report (2024 Y), p28](https://app.finbar.com/go?id=T-9bd7818491cc46ac985fe49e59f22e86)
49. [ROCHE HLDG P — Full financial report (2024 Y), p3](https://app.finbar.com/go?id=P-1ae0c31e14684c4db9d77c4c4f87064e)
50. [www.roche.com](https://www.roche.com/about/history.htm)
51. [assets.roche.com](https://assets.roche.com/imported/07_Annual_Report_2022.pdf)
52. [ROCHE HLDG P — Full financial report (2023 Y), p106](https://app.finbar.com/go?id=P-d6bdeb88c0a947a69a35b1676d0968f0)
53. [ROCHE HLDG P — Full financial report (2015 Y), p85](https://app.finbar.com/go?id=P-aa6e749b0e0645e29b0fa61c087b1b7c)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.